Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
TRAIL R2 agonist
DRUG CLASS:
TRAIL R2 agonist
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
ABBV-621 (3)
AMG 655 (1)
INBRX-109 (1)
BI 905711 (0)
CPT (0)
CTB-006 (0)
DS-8273 (0)
ONKT101 (0)
TLY012 (0)
IGM-8444 (0)
RG7425 (0)
AMG 951 (0)
CS-1008 (0)
ABBV-621 (3)
AMG 655 (1)
INBRX-109 (1)
BI 905711 (0)
CPT (0)
CTB-006 (0)
DS-8273 (0)
ONKT101 (0)
TLY012 (0)
IGM-8444 (0)
RG7425 (0)
AMG 951 (0)
CS-1008 (0)
›
Associations
(5)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies (NCT03082209)
Phase 1
AbbVie
AbbVie
Completed
Phase 1
AbbVie
Completed
Last update posted :
12/09/2022
Initiation :
03/20/2017
Primary completion :
01/21/2022
Completion :
01/21/2022
KRAS
|
KRAS mutation • RAS mutation
|
Avastin (bevacizumab) • Venclexta (venetoclax) • 5-fluorouracil • irinotecan • leucovorin calcium • eftozanermin alfa (ABBV-621)
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma (NCT02983006)
Phase 1
NYU Langone Health
NYU Langone Health
Completed
Phase 1
NYU Langone Health
Completed
Last update posted :
10/18/2021
Initiation :
10/01/2016
Primary completion :
12/23/2019
Completion :
01/01/2021
IL2
|
Opdivo (nivolumab) • DS-8273
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer (NCT01033240)
Phase 2
Daiichi Sankyo, Inc.
Daiichi Sankyo, Inc.
Completed
Phase 2
Daiichi Sankyo, Inc.
Completed
Last update posted :
04/08/2021
Initiation :
07/09/2010
Primary completion :
07/13/2012
Completion :
09/09/2013
AFP
|
sorafenib • tigatuzumab (CS-1008)
A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors (NCT02558140)
Phase 1
Hoffmann-La Roche
Hoffmann-La Roche
Completed
Phase 1
Hoffmann-La Roche
Completed
Last update posted :
04/04/2018
Initiation :
10/11/2015
Primary completion :
11/06/2017
Completion :
11/06/2017
FAP
|
FAP expression
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer (NCT01307891)
Phase 2
University of Alabama at Birmingham
University of Alabama at Birmingham
Completed
Phase 2
University of Alabama at Birmingham
Completed
Last update posted :
10/26/2017
Initiation :
03/01/2011
Primary completion :
06/01/2016
Completion :
06/01/2017
HER-2 • PGR
|
HER-2 amplification • HER-2 negative
|
albumin-bound paclitaxel • tigatuzumab (CS-1008)
A Study of PRO95780 in Combination With Rituximab in Patients With Non-Hodgkin's Lymphoma That Has Progressed Following Previous Rituximab Therapy (APM4083g) (NCT00517049)
Phase 2
Genentech, Inc.
Genentech, Inc.
Completed
Phase 2
Genentech, Inc.
Completed
Last update posted :
06/06/2017
Initiation :
03/01/2008
Primary completion :
12/01/2009
Completion :
12/01/2009
CD20
|
CD20 positive
|
Rituxan (rituximab) • drozitumab (RG7425)
A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection (NCT03083743)
Phase 3
Shanghai Gebaide Biotechnology Co., Ltd.
Shanghai Gebaide Biotechnology Co., Ltd.
Unknown status
Phase 3
Shanghai Gebaide Biotechnology Co., Ltd.
Unknown status
Last update posted :
03/20/2017
Initiation :
10/01/2016
Primary completion :
10/01/2017
Completion :
06/01/2018
ALK
|
EGFR mutation • ALK positive • ALK mutation • EGFR positive • EGFR negative
|
dulanermin (AMG 951)
Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Ovarian Cancer (NCT01940172)
Phase 1b
TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals
Completed
Phase 1b
TetraLogic Pharmaceuticals
Completed
Last update posted :
01/14/2016
Initiation :
11/01/2013
Primary completion :
09/01/2015
Completion :
12/01/2015
MUC16
|
birinapant (IGM-9427) • conatumumab (AMG 655)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login